Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

This publication has 99 references indexed in Scilit:

• Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
  Drug Resistance Updates, 2008
• Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics
  Experimental Hematology, 2008
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
• Suppressor of cytokine signaling 3 controls lysosomal routing of G‐CSF receptor
  The EMBO Journal, 2007
• The mannan-binding lectin pathway and lung disease in cystic fibrosis—dysfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier
  Clinical Immunology, 2006
• Phosphatidylinositol 3-kinase p85α regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population
  Diabetologia, 2006
• Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
  British Journal of Cancer, 2006
• Validating Stat3 in cancer therapy
  Nature Medicine, 2005
• The STATs of cancer — new molecular targets come of age
  Nature Reviews Cancer, 2004
• A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain
  Biochemical and Biophysical Research Communications, 1989